MOBILIZING NATURE’S DEFENDERS
FOR NEXT-GENERATION THERAPEUTICS
BACTERIOPHAGE INNOVATION FOR
NEXT-GENERATION MEDICAL HEALTH SOLUTIONS
Antimicrobial resistant (AMR) bacteria, or ‘super bugs’, are predicted by the World Health Organization (WHO) to kill up to 10 million per year by 2050. That's the equivalent to 1 person every 3 seconds.
Also known as phages, these naturally occurring viruses have been battling bacteria in an evolutionary arms race for all eternity by infiltrating, and destroying bacterial colonies with pinpoint precision.
While phage have been used to treat people for more than a century, their full potential as medical solutions is yet to be exploited. In parallel, low-cost, broad-spectrum antibiotics, once considered to be miracle drugs, provided a lifeline to patients with serious infections. Now, surging antibiotic resistance and advances in phage biology have revived the potential of phage as a viable alternative.
By studying the natural history of bacterial infections, we have developed a holistic strategy that leverages bacteriophages to cut-off foundational evolutionary pathways for colonization.
PHIOGEN creates breakthrough antimicrobial solutions by using state-of-the-art capture technology and human-like model systems that mimic the complexity of real infections. We select hyper-functional phages that target bacterial vulnerabilities and utilize proprietary machinery to drive evolutionary changes that overcome resistance.
PHIOGEN INC was founded in 2023 to commercialize technology developed at TAILΦR Labs, a personalized phage therapy center of Baylor College of Medicine.
Located at the Texas Medical Center Innovation Hub, PHIOGEN’s experienced team of experts are building on a decade of research in phage biology to develop next generation therapeutics.
Our innovative platform capitalizes on the successes of personalized phage therapy, while our game-changing technology opens the door to a sustainable business model in which we can treat entire patient populations with a single solution.
Born out of innovation, PHIOGEN was founded by Baylor College of Medicine and is supported by BCM Ventures. We have partnered with TAILOR Labs, the US’s first phage discovery and manufacturing center, to bring scientific breakthroughs to patients at a population level. This combination of forces has equipped PHIOGEN with world-class science, unmatched commercial expertise and unlimited clinical access in the world’s largest medical center.
Tailored Antibacterials and Innovative Laboratories for phage (Φ) Research (TAILΦR) is housed in the Texas Medical Center. It is a non-profit initiative delivering personalized and effective treatments for antibiotic-resistant bacterial infections.
Baylor College of Medicine Ventures aims to support university innovators, entrepreneurs and industry to encourage the commercialization of ideas and identify market opportunities or collaborative ventures that benefit society.
PHIOGEN’s unique platform is underpinned by innovative technology and expert insight to generate revolutionary breakthrough in phage biology. The proprietary platform consolidates state-of-the-art technologies inside a single structured research and development process focused on generating commercial solutions.
Unravelling the full functionality and harnessing the power of bacteriophages requires a multidisciplinary, end-to-end scientific approach with an in-depth biological understanding of how phages naturally interact with bacteria. Our breakthrough platform enables us to discover rare phages with highly targeted neutralizing capabilities, evolve hyper-lytic phages to overcome resistance, and test them in high-throughput biological models, resulting in cultivated antimicrobial solutions that successfully productize bacteriophage to improve clinical outcomes.
Click on the Icons to learn more…
We have developed the world’s first and only bacteriophage mass capture device, where we are able to deploy on phage reconnaissance missions, collecting and filtering billions of phage from where they naturally occur; accelerating sample collection from 4 days to just under 4 hours. After collecting an army of phages, we hand pick the best defenders and track their kill activity against a large panel of drug resistant isolates collected from infected patients.
PHIOGEN uses state-of-the-art biomedical methods to perform a thorough vetting of all enhanced phages. This includes but is not limited to sequencing and genome annotation in CLIA certified labs, streamlining production to maximize cost-efficiency, optimizing storage conditions for stable formulations, rigorous screening for safety and phage-antibiotic combinatorial testing for synergy, among many others. By characterizing our phages from head-to-tail, we can get an accurate indication of interactions and behavior to curate high-performing antimicrobial solutions.
Our access to stem-cell derived 3D culture systems means PHIOGEN can effectively grow and study cells that simulate physiological conditions of infection. Biological media from humans e.g. blood and urine are also used to replicate real world settings. This effectively creates an artificial patient to ensure the phages work in the target environment.
PHIOGEN uses a patented device that drives directed evolution of new phage variants, accelerating lengthy processes that may take years to occur, or never happen at all, into mere hours or days.
This is how we are able to enhance intrinsic characteristics that can overcome resistance through naturally selecting and implementing pressure – enabling the cycling through millions of generations until a single mutation occurs to reveal a next-gen super phage.
We strategically design, produce and test different combination of Good Manufacturing Practice (GMP) grade phage with elite infection-fighting capabilities to identify optimal formulations for clinical trials.
Our focus during this stage is to drive a synergistic effect and ensure that selected phages work in unison to target various pathways of infection.
Our use of bioclimatic screening eliminates candidates early in the development process, de-risking assets and reducing unnecessary trials.
We validate final formulation using complex in-vivo challenge models that mimic systemic infection to ensure safety and efficacy.
Our pre-clinical approach ensures the highest probability of success in improving clinical outcomes.
Chief Executive Officer
Ms. Amanda Burkardt has over 15 years of experience commercializing technology, consulting, and scientific research both domestically and internationally.
Chief Operations Officer
Dr. Mayukh Das has over 19 years of experience developing phage-based products and managing research and development operations inside academia, biotech start-ups and large pharma.
Clinical Operations Manager
Dr. Austen Terwilliger is an accomplished academic researcher with extensive experience in molecular microbiology, bacterial pathogenesis, wastewater epidemiology, and phage biology.
Dr. Justin Clark holds over 15 years of experience as an accomplished molecular biologist, inventor, and bioinformatician.
Dr. Keiko Salazar has been working with phages and their pathogenic hosts for over 9 years, starting as a student intern at Sandia National Laboratories.
Ms. Pauline Kim has over 5 years of research laboratory experience in a variety of verticals from chemistry to microbiology.
Mr. Jamie Bailey has 20 years of accounting and finance experience, leading and overseeing multidisciplinary teams in accounting, planning, treasury and tax functions.
Dr. Anthony Maresso has 20 years experience in genetics, biochemistry, and cell biology and is the Joseph Melnick Chair and Professor in Molecular Virology at Baylor College of Medicine.
Dr. Joseph Petrosino has over 25 years of experience in microbiology, commercialization, and leadership .
Our pipeline is focused on delivering novel classes of therapeutics, derived from bacteriophages. The disease targets in our pipeline include several drug-resistant bacteria on the World Health Organization's global priority pathogen list.
Evolved bacteriophages created on our platform have already been successfully administered to patients under emergency use authorization (EUA) provided by the FDA in order to administer rescue treatment in critically-ill patients where antibiotics have failed.
PHIOGEN’s commercialization plan features establishment of partnerships, joint ventures, and licensing arrangements with industry to fuel bacteriophage innovation needs.
Our proprietary technology platform can be deployed on new targets and generate product candidates in an accelerated time period.
If you would like to discuss partnering opportunities, contact us.
PHIOGEN is working with academic research, instituties, and other phage companies to fuel development and accelerate our pipeline.
We are always looking to collaborate and recruit innovation to our platform to help bridge the gap between research and commercialization.
If you are interested in collaborating, contact us.
16th October, 2023
1st June, 2023
6th June, 2023